PrEP Archives – Treatment Action Group

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

June 20, 2024
Dorrit Walsh

Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.

For Us By Us: PrEP in Black America

February 8, 2023
Dorrit Walsh

For Us By Us: PrEP in Black America, A Master Plan for HIV Prevention in Black America is a collaborative project from the PrEP in Black America coalition, which includes Treatment Action Group, PrEP4All, AVAC, Atlanta Black Women Leaders on PrEP, Equity & Impact Solutions, iStrive, Positive Impact Health Centers, and Red Hot.

The Power of PrEP

February 2, 2023
Dorrit Walsh

To mark National Black HIV/AIDS Awareness Day on February 7, Treatment Action Group (TAG) is co-hosting a webinar “The Power of PrEP” in coalition with PrEP4All, Atlanta Black Women, AVAC, and iStrive.

What’s on the Horizon for Long-Acting Pre-Exposure Prophylaxis (PrEP)? Fact Sheet

October 26, 2021
Dorrit Walsh

Long-acting pre-exposure prophylaxis (PrEP) will be a groundbreaking HIV prevention tool. The approach provides an option to receive intermittent doses of PrEP instead of taking daily pills. This handout provides an update on the development of long-acting PrEP and future…

Treatment Action Group Statement on Early Findings from HPTN 084

November 12, 2020
Dorrit Walsh

Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.

The Future of Biomedical HIV Prevention Trials: Researcher Viewpoints and Community Survey

March 6, 2020
Dorrit Walsh

This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…

Treatment Action Group Statement on the HVTN 702 HIV Vaccine Trial Results

February 3, 2020
Dorrit Walsh

Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.

TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP

November 11, 2019
Dorrit Walsh

Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.

Eight HIV/AIDS Research, Policy, and Advocacy Organizations File an Amici Curiae Brief in Staley v. Gilead – Background and Next Steps

October 30, 2019
Dorrit Walsh

On October 25, 2019, eight HIV/AIDS research, policy, and advocacy organizations filed an amicus brief in the U.S. District Court, in San Francisco, CA, in support of the plaintiffs in Staley v. Gilead.

Advocates Debrief on the Science of Daily F/TAG vs. TDF/FTC as PrEP

October 9, 2019
Dorrit Walsh

TAG, AVAC, The Well Project and the Women’s Research Initiative (WRI) co-convened this webinar on Monday, October 7. It was the first in a two-part series, responding to advocates’ desire to better understand the research to date on F/TAF as…